IL-33 Antibody

• Catalog Number: orb1239503
• Category: Antibodies
• Description: IL-33 Antibody
• Target: IL33
• Clonality: Polyclonal
• Isotype: IgG
• Conjugation: Unconjugated
• Reactivity: Human, Mouse
• Predicted Reactivity: Rat
• Form/Appearance: Liquid
• Concentration: 1 mg/mL
• Buffer/Preservatives: IL-33 Antibody is supplied in PBS containing 0.02% sodium azide.
• Purification: IL-33 Antibody is affinity chromatography purified via peptide column.
• Immunogen: Anti-IL-33 antibody (orb1239503) was raised against a 17 amino acid synthetic peptide from near the center of human IL-33. The immunogen is located within the 150-200 amino acids of IL-33.
• UniProt ID: O95760
• MW: Predicted: 31kDObserved: 33kD
• Tested applications: ELISA, IF, IHC-P, WB
• Antibody Type: Primary Antibody
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Alternative names: IL-33 Antibody: DVS27, IL1F11, NF-HEV, NFEHEV, C9o
• Research Area: Immunology & Inflammation
• Note: For research use only
• NCBI: NP_254274

Western Blot Validation of IL-33 in A20 Cells. Loading: 15 µg of lysates per lane. Antibodies: IL-33, orb1239503, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane A: 1 µg/mL, Lane B: 2 µg/mL.

Western Blot Validation of IL-33 with Human Recombinant Protein. Loading: 5ng (1) and 25ng (2) of IL-33 partial human recombinant protein. Antibodies: IL-33, orb1239503, 1 µg/mL, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Il-33 partial human recombinant protein: 112-270aa, 17.9kD, 36kD band is the dimer.

Western Blot Validation of IL-33 in Human Lymph Node. Loading: 15. µg of human lymph node lysate. Antibodies: IL-33, orb1239503, 2 µg/mL, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation of IL-33 in Human Lung. Loading: 15. µg of human lung lysate. Antibodies: IL-33, orb1239503, 2 µg/mL, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Immunofluorescence Validation of IL-33 in Human Lymph Node. Immunofluorescent analysis of 4% paraformaldehyde-fixed human lymph node tissue labeling IL-33 with orb1239503 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Immunohistochemistry Validation of IL-33 in Human Lymph Node. Immunohistochemical analysis of paraffin-embedded human lymph node tissue using anti-IL-33 antibody (orb1239503) at 2.5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Induced Expression Validation of IL-33 in Human Skin Fibroblasts (Ivanov et al., 2010). Protein expression of IL-33 in human skin fibroblasts following alpha-irradiation were detected by anti-IL-33 antibodies. IL-33 levels were increased 1–4 h after α-irradiation.

Regulated Expression Validation of IL-33 in Human Skin Fibroblasts (Ivanov et al., 2010). Protein expression of IL-33 in human skin fibroblasts following alpha-irradiation were detected by anti-IL-33 antibodies. IL-33 levels were increased after α-irradiation, which were inhibited by treatment of PPP.